News and Resources

New Ebola vaccine study begins in Nigeria

MHRP began a new Ebola vaccine study last week at its site in Abuja, Nigeria in collaboration with the Nigerian Ministries of Defence and Health. The vaccine used in the study (RV429) is the monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline…